Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3636219 A
Publication typeGrant
Publication dateJan 18, 1972
Filing dateMar 2, 1964
Priority dateMar 2, 1964
Publication numberUS 3636219 A, US 3636219A, US-A-3636219, US3636219 A, US3636219A
InventorsRudolf Culik, Jurg A Schneider
Original AssigneeDu Pont
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Anticholinergic compositions containing certain thiazolines or imidazolines
US 3636219 A
Abstract  available in
Images(11)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent 3 636 219 ANTICHOLINERGIC C0l\ .[POSlTIONS CONTAIN- ING CERTAIN THIAZOLINES 0R IMIDAZOLINES Rudolf Culik, Kennett Square, Pa., and Jurg A. Schneider,

Wilmington, Del., assignors to E. I. du Pout de Nemours and Company, Wilmington, Del.

No Drawing. Filed Mar. 2, 1964, Ser. No. 348,884

Int. Cl. A61k 27/00 US. Cl. 424-265 48 Claims This invention relates to pharmaceutical compositions useful for both human and veterinary applications. More particularly, this invention relates to synergistic utilization of one or more centrally acting anticholinergic substances and one or more of a class of central nervous sys tern depressants.

The disclosure herein should not be taken as a recommendation to use the disclosed invention in any way without full compliance with US. Food and Drug laws and other laws and governmental regulations which may be applicable.

According to the present invention, an amazing synergism has been noted between a centrally acting anticholi nergic and compounds in a class generically identified as 2-arylamino-Z-thiazolines and 2-arylamino-2-imidazolines. While the thiazolines and imidazolines themselves have activity, some to a remarkable extent, as regulators and in particular depressant of the central nervous system, we have now discovered that, when used with a centrally acting anticholinergic, the synergistic combination according to this invention effects a. profound action, producing a striking depression of central nervous system control of skeletal muscle as well as a striking loss of responses to painful stimuli. This effect resembles a deep surgical anesthesia, producing unconsciousness in the recipient in a very short time.

Centrally acting anticholinergics are a well-recognized class of pharmacologically active substances. As is well known and understood by pharmacologists, these anticholinergics can be naturally occurring or synthetic and are those substances which act to inhibit and have a highly selective blocking action on effector organs innervated by postganglionic cholinergic nerves. As is known to persons skilled in this art, anticholinergic agents containing a quaternary nitrogen moiety are of course not centrally actmg.

Perhaps the best known centrally acting anticholinergics are the natural occurring alkaloids of the belladonna plants. The two most important of these alkaloids are atropine (dl-hyoscyamine) and scopolamine (l-hyoscine) and these two materials are the preferred synergists according to the present invention because of their significantly outstanding synergizing action with the 2-arylamino-Z-thiazolines and the 2-arylamino-2-imidazolines. Also of special importance because of outstanding activity are the centrally acting anticholinergic glycolates.

However, the use of all centrally acting anticholinergic substances is intended to be embraced within the concept of the present invention. Illustrative of such anticholinergics are the following:

Adephenine (registered trademark), also identified as Trasentine (registered trademark) and Z-diethylaminoethyl diphenylacetate ice benactyzine, also identified as beta-diethylaminoethyl benzilate benztropine, also identified as 3-diphenyhnethoxytropane caramiphen, also identified as 1-phenylcyclopentanecarboxylic acid, diethylaminoethyl ester cyclopentolate, also identified as l-hydroxy-alphaphenylcyclopentaneacetic acid, Z-dimethylaminoethyl ester cycrimine, also identified as alpha-cyclopentylalpha-phen yl-l-piperidinepropanol ditran, also identified as N-ethyl-3-piperidyl phenyl cyclopentyl glycolate ethopropazine, also identified as IO-(Z-diethylaminopropyl) phenothiazine oxyphencyclimine, also identified as 1-methyl-1,4,S,6-tetrahydro 2 pyrimidylrnethyl alpha-cyclohexylalphaphenylglycolate piperidolate, also identified as N-ethyl-3-piperidyl diphenylacetate systral, also identified as chlorphenoxamine and beta-dirnethylaminoethyl (p-chloro-alpha-methylbenzhydryl) ether tricyclamol, also identified as procyclidine and alpha-cyclohexyl-alpha-phenyl-l-pyrrolidinepropanol trihexyphenidyl, also identified as alpha-cycloheXyl-alphaphenyl-l-piperidinepropanol In addition to the above-mentioned anticholinergics, other illustrative materials include homatorpine, atroscine, eucatropine, syntropan (amprotropine), pavatrine, bauthine (methantheline), pro-banthine (propantheline), oxypenonium (antrenyl) penthienate (monodral), diphenmethanil (prantal), mepiperphenidol (darstine), dicyclomine (bentyl), aminopentamide (centrine), dibutoline and the like.

As will be readily understood, the centrally acting anticholinergics will most often be used in the form of an acid addition salt with an acid having a pharmaceutically aceptable anion. The term pharmaceutically acceptable anion has a definite meaning to one skilled in the art,

namely, a non-toxic anion of any of the simple acids commercially used to neutralize basic medicinal agents. These acids include, for example, hydrochloric, hydrobromic, hydriodic, sulfuric, succinic, maleic, tartaric, citric, glyco'lic, and others. The pharmaceutical activity of the molecule is primarily but not necessarily exclusively a function of the cation.

By way of further illustration of the salts of anticholinergic agents, it can be mentioned that atropine is preferably used as the hydrobromide, hydrochloride, methylbrornide, methylnitrate, salicylate, sulfate, atropinesulfuric acid, valerate, aurichloride, platinichloride, oxalate or picrate; scopolamine as the hydrobromide, hydrochloride, aurichloride, auribromide, picrate, methylbromide, methylnitrate or aminoxide; Adephenine (registered trademark) as the hydrochloride; 'benactyzine as the hydrochloride; benztropine as the methanesulfonate; caramiphen as the hydrochloride or ethanedisulfonate; cycrimine as the hydrochloride; oxyphencyclimine as the hydrochloride; systral as the hydrochloride; and trihexyphenidyl as the hydrochloride.

The second essential ingredient of the synergistic compositions of the present invention is a 2-arylamino-2- thiazoline or a 2-arylamino-2-imidazoline having central nervous system depressant activity. Suitable Z-arylaminothiazolines or 2-arylamino-2-imidazolines include those of the following formulas:

NH-C

R xix-n X-(L-R In each of the above formulas, X is S or N; R, R R and R are the same or different and can each be hydrogen or an alkyl group of 1 through 4 carbons with the total number of carbons in these 4 substituents being a maximum of 8. In the compounds of Formulas 1 through 5, the hydrogen atoms in the naphthyl, the partially reduced naphthyl or the indanyl groups may be replaced with substituents such as halogen, e.g., chlorine, bromine, fluorine and iodine, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethyl and trifluoromethoxy. Up through three such substituents can be present.

In Formula 6, A can be hydrogen, alkyl of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxy of 1 through 4 carbons, and preferably 1 or 2 carbons, or halogen including chlorine, bromine and fluorine; B can be alkyl of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxy of 1 through 4 carbons and preferably 1 or 2 carbons, or halogen including chlorine, bromine and fluorine; and C can be hydrogen, alkyl of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxy of 1 through 4 carbons and preferably 1 or 2 carbons, halogen including chlorine, bromine and fluorine, alkylthio of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxyalkyl wherein the alkoxy portion has 1 or 2 carbons and the alkyl portion has 1 or 2 4 carbons, alkylamino of 1 or 2 carbons, dialkylamino where the alkyl group can be the same or dilferent and each has 1 or 2 carbons, trifiuoromethyl or trifluoromethoxy.

PREPARATION The thiazoline compounds used in this invention are made in the manner described for the thiazoline compounds of U5. Pat. 2,027,030. Appropriate substitution of starting materials such as naphthyl-isothio-cyanates and indanyl-isothio-cyanates for the phenyl-isothiocyanates will produce the desired compounds.

The imidazoline compounds used in this invention are made in the manner described for the imidazolines of US. Pat. 2,899,426. Appropriate substitution of starting materials as will be known to an expert in the art produces the desired compounds.

Generally, the compounds used in this invention are crystalline solids. They can be readily prepared by reaction of the appropriately selected arylamine and an appropriate alkyl thiocyanate to form the corresponding N-aryl-N'-(beta-substituted ethyl)thiourea, followed by heating in a suitable solvent to close the thioazoline ring. Alternatively, the thiourea can be prepared by reaction between an appropriate aryl thiocyanate and an appropriate alkylamine followed by the ring closure.

In the foregoing procedures, the reaction between the amine and thiocyanate can conveniently be carried out in a suitable inert organic solvent including both aromatic and aliphatic hydrocarbon solvents. Halogenated, oxygenated or nitrated hydrocarbon solvents are useful. Representative solvents are benzene, chloroform, carbon tetrachloride, ethylene dichloride, chlorobenzene, toluene, xylene, nitrobenzene, and nitrotoluene. Temperatures in the range from 0 to C. are suitable.

By reference to the reaction described above, it can be seen that in the ordinary practice of the process of the invention, the thiazolines, and the irnidazolines produced will be hydrobromides, hydrochlorides, hydriodides, methanesulfonic acids or p-toluenesulfonic acids. These acids can be converted to other pharmaceutically acceptable acids by procedures well known to those skilled in the art. One highly useful method comprises contacting the acid addition salt with a basic anion exchange resin, for example, a highly basic compound such as the one available from Rohm & Haas Company under the name Amberlite IRA-400. This resin is a polyquaternary ammonium compound which is prepared by chloromethylatiug a highly cross-linked copolymer of styrene and divinylbenzene followed by treatment of the chloromethylated material with a tertiary amine such as trimethylamine. To prepare an acid addition salt of this invention, for example, the citrate, the resin is first contacted with an aqueous solution of citric acid whereupon an anion exchange takes place converting the quaternary halide to the citrate. The citrate resin is then contacted with an acid addition salt prepared as described above and a further anion exchange takesplace converting the acid addition salt to the citrate and leaving the anion of the orginial salt on the resin. The citrate salt can be recovered from the eluate by a number of methods such as evaporation or solvent precipitation. This same procedure can be used to prepare nitrates, sulfates, acetates and other acid addition salts.

Illustrative of the compounds within the scope of Formula 1 above are the following:

2- 3 ,4-dichlorol-naphthyl am ino -2-thi azol ine 2- 3,4-dichloro-l-naphthyl amino -2-imidazoline 2- 3-bromol -naphthylamino) -4-metthyl-2-thiazoline 2- (3-bromo-l-naphthylarnino) -4-rnethyl-2-imidazoline.

2- (4-ethyll-naphthylamino -4,S-dimethyl-Z-thiazoliue 2- (4-ethyl-1-naphthylamino -4,S-dimethyl-Z-imidazoline 2-(3 ,4,5-triiodo- 1 -naphtl1ylamino -2-thiazoline 2- 3,4,5 -triiodo-1-naphthylamino -2-imidazo1ine 2- 3,4-bismethylthiol-naphthylamino -4-butyl-2- thiazoline 2- 5,6,7 ,8-tetrahydro-3,4,5-triiodo-1 -naphthylamino) -4,5-

dimethyl-Z-imidazoline 2- ,6,7,8-tetrahydro-4-isopropyll-naphthylamino) -2- thiazoline 2- 5,6,7,8-tetrahydro-4-isopropy1- l-naphthylamino -2 imidazoline 2- (5,6,7,8-tetrahydro-4-trifiuor0methyl-l-naphthylamino Z-thiazolines 2- 5,6,7,8-tetrahydro-4-trifluor0methyll-naphthylamino Z-imidazoline 2- (5,6,7,8-tetrahydro-4-trifluoromethoxyl-n aphthylamino) -2-thiazolines 2- 5 6,7,8-tetr ahydro-4-trifluoromethoxyl-naphthylamino) -2-imidazoline Illustrative of the compounds within the scope of Formula 5 above are the following:

2- (4-iudanylamino) -2-thiazoline 2- 4-indanylamino) -2-irnidazoline 2-(2-chloro-4-indanylan1ino) -2-thiazoline 2-(2-chloro-4-indanylamino)-2-imidazoline 2- 2,5 -diiodo-4-indanylamino -2-thiazoline 2- 2,5 -diiodo4-indanylamino -2-imidazoline 2-(3,5-bispropylthio-4-indanylamino)-2-thiazoline 2- 3 ,5 -bispropylthio-4-indanylamino -2-imidazoline 2-(2-methyl-4-indany1amino)-2-thiazoline 2-(2-methyl-4-indanylamino)-2-imidazoline Illustrative of the compounds within the scope of Formula 6 are the following:

2- 2-toluidino -2thiazoline 2- Z-toluidino -2-imidazoline 2- 2,3-dimethylanilino )-2-thiazoline 2- (2,3 -dimethylanilino) -2-imidazoline 2-( 3-chloro-2-methylanilino -2-thiazoline 2- 3 -chloro-2-methylanilino -2-imidazoline 2- (Z-ethylanilino -2-thiazoline 2- 2-ethylanilino -2-imidazo1ine 2-( 3,4-dimethylanilino) -2-thiazoline 2- 3 ,4-dimethylanilino -2irnidazoline 2-( 3-isopropylaniliuo -2-thiazoline 2- 3-isopropylanilino -2-imidazoline 2- (2,3 ,4-trichloroanilino -2thiazoline 2- (2,3 ,4-trichloroanilino) -2-imid azoline 2- (4-methoxy-2-methylanilino -2-thiaz0line 2- (4-methoXy-2-methylanilino -2-imidazoline 5-methyl-2- 2,3-dimethylanilino -2-thiazo1ine S-methyl-Z- 2,3-dimethylanilino -2-imidazoline 4-ethyl-2- (2, 3 -dimethylanilino -2-thiazoline 4-ethy1-2- (2,3-dimethylanilino -2-imid azoline 4,4-dimethyl-2- 2-methyl-3-chloroanilin0 -2-thiazoline 4,4-dimethyl2- (Z-methyl-B-chloroanilino -2-imidazoline 5 -butyl-2- (Z-methylanilino -2-thiazoline 5-butyl-2- Z-methylanilino -2-imidazoline 2- Z-dimethylaminoanilino) -2-thiazoline 2- (Z-dimethylaminoanilino -2-imidazoline 2- (3 -methylthioanilino -2-thiazoline 2- (3-methylthio anilino -2-imidazolinne 2- (Z-trifiuoromethylanilino) -2-thiaz0line 2- (Z-trifiuoromethylanilino -2-imidazoline 2- (2-trifluoromethoxy-3-methylanilino -2-thiazoline 2- 2-trizfluoromethoXy-3 -methylanilino -2-imidazoline 2- 2,4,5 -trimethylanilino) -2-thiazoline 2-(2,4,5-trimethylanilino -2-imidazoline 4-methyl-2- 2-methyl-5-isopropylanilino -2-thiazoline 4methyl-2- 2-methyl-5 -isopropylanilino 2-imidazoline 2- 2,5 -dimethoxyanilino -2-thiazoline 2-(2,5-dimetboxyani1ino)-2-imidazoline S-methyl-Z- 2,4-dimethoxy-5-chloroanilino -2- thiazoline S-methyl-Z- (2,4-dimethoxy-S-chloroanilino -2- imidazoline 2-( Z-fluoroanilino) -2-thiazoline 2- 2- fluoroanilino -2-imidazoline 2- (2-bromo-4-methylanilino -2-thiazoline 2- 2-bromo-4-methy1anilino) -2-imidazoline 8 2-( 2,5 -diethoxyanilino) -2-thiazoline 2- 2,5 -diethoxyanilino) -2-imidazoline 2- 3-chloro-4-methylanilino) -2.-thiazoline 2- 3-chloro-4-methylanilino -2-imidazoline 2- 2,6-diethylanilino) -2-thiazoline 2- 2,6-diethylanilino -2-imidazoline 2- 4-chloro-Z-trifiuoromethylanilino) -2-thiazoline 2- (4-chloro-2-tritluoromethylanilino -2-imidazoline 2- 3-chloro-4-fluoroaniliuo )-2-thiazoline 2- 3-chloro-4-fiuoroanilino -2-imidazoline 2- (4 fluoro-2-methylauilino -2-thiazoline 2-(41fluoro-2-methylani1in0)-2-imidazoline In the practice of the present invention it should be fully appreciated that administration of the anticholinergic and the thiazolines and the imidazolines for the intended profound depressant effect will be more or less concurrent, i.e., united in action, and not necessarily simultaneously, i.e., in the same pharmaceutical formulation or dosage unit. Thus, it will be understood that the synergistic benefits of the present invention will be readily obtainable even though either one or the other of the two essential materials may be administered somewhat prior to or subsequent to the administration of the other. For example, for gradual inducement of profound central nervous system depression with apparent unconsciousness in a patient, it may under some circumstances be desirable to administer first the thiazoline or the imidazoline, perhaps orally, followed by within say 30 minutes or an hour by administration, perhaps by injection, of the synergistic amount of the anticholinergic agent.

Of course, the precise length of time which can elapse between administration of the anticholinergic and the thiazoline or the imidazoline, or vice versa, to still obtain the synergistic co-action of the compounds has not been determined for each combination of the two different materials possible according to this invention. This precise time lag will depend on the amount of each administered, the condition of the recipient, the absorption characteristics of each material, the dosage form or method, the nature of the effect desired, etc., as will be determined by the attendant physician or veterinarian. Generally speaking, it is believed that provided the dosage of each are sufficient, the synergistic action isobtainable if the two components are administered within, say, 2 or 3 hours of each other.

The amount of each of the two essential materials to be administered will of course also depend upon the variables just mentioned but, in general, the thiazoline or imidazolline will be administered in the range of about 0.1 to milligrams per dose and in the range of about 0.1 to 500 milligrams per day. For the synergistic eifect, for each part by weight of thiazoline or imidazoline used, there will usually be used from about 0.5 to about 30 parts by weight of anticholinergic agent, and preferably about 0.5 to about 5 parts by weight of the latter. The absolute potency of each of the ingredients will of course be the prime determining factors.

As mentioned above, in general, the physician or veterinarian will, of course, determine the dosage of each and the total dosage which will be most suitable for a particular application, and as might be expected, it will vary with the age, weight and general health of the patient under treatment and with various other factors which will be determined by the physician or veterinarian in attendance. When they are administered orally a larger quantity will be required to produce the same effect as a smaller quantity given parenterally. Parenteral administration of from 0.1 mg. to 250 mg. of each active agent should be suitable to obtain some effect. Administration can also be by vapor or spray through the mouth or nasal passages.

In animal tests to date no synergism of cardiovascular actions has thus far been noted. Furthermore, based on tests to date, it is believed that the surprising synergism in inducement of profound central nervous system depression obtained according to the present invention is achieved without at the same time substantially altering the normally expected effect of centrally acting anticholinergic agents on the heart rate.

In the practice of this invention, the active pharma ceutical agents may be administered alone but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets or capsules containing such excipients as starch, milk sugar, certain types of clay, etc. They may be ad ministered orally in the form of elixirs or oral suspensions which may contain coloring and flavoring agents. They may be injected parenterally and for this use may be prepared in the form of sterile aqueous solutions containing other solutes such as saline or glucose in sufficient quantity to make the solution of isotonic. For intramuscular administration compositions of the compounds of this invention may be prepared in an oil base such as peanut or sesame oil.

Compositions useful in the practice of the present invention may take a variety of forms. Various diluents may be employed and the percentage of active ingredients may be varied. It is necessary that the active ingredient or ingredients form a proportion of the com position such that a suitable dosage form will be obtained. Obviously several dosage unit forms can be administered at about the same time. Although compositions with less than 0.005% by weight of either active ingredient are suitable, it is preferred to use compositions containing not less than 0.005% of either active agent because otherwise the amount of carrier becomes excessively large. Activity normally increases with the concentration of the active agent. The percentage by weight of single or combined active agents can be 10, 50, 75, 95 or even higher. Dosage unit forms may be prepared with a minor proportion of a carrier and a major proportion of active materials and vice versa.

The following examples are given solely for the purpose of illustration and are not to be construed as limitations of this invention, many variations of which are possible without departing from the spirit or scope thereof.

EXAMPLE 1 A large number of unit capsules are prepared for oral administration by mixing the following ingredients:

Parts by weight 2-(5,6,7,8 tetrahydro 1 naphthylamino) 2- thiazoline 650 Scopolamine hydrobromide 1,300 Lactose U.S.P. 8,000 Dry pyrogenic silica Si with particle size of 0.015 micron, surface area of 200 m. /gm., and

bulk density of 2.2 lbs/cu. ft. (Cabosil,

Cabot Corp.) 50

After mixing, the mixture is screened through a mesh screen and encapsulated in No. 3 two-piece hard gelatin capsules.

EXAMPLE 2 A large number of unit capsules are prepared by oral administration by mixing the following ingredients:

Parts by weight 2-(5,6,7,8 tetrahydro 1 naphthylamino) 2- imidazoline 650 Scopolamine hydrobromide 1,300 Lactose U.S.P. 8,000 Dry pyrogenic silica SiO with particle size of 0.015 micron, surface area of 200 m. /gm., and

bulk density of 2.2 lb./cu. ft. (Cabosil,

Cabot Corp.)

10 After mixing, the mixture is screened through a 40 mesh screen and encapsulated in No. 3 two-piece hard gelatin capsules.

EXAMPLE 3 The active ingredients of Example 1 (20 parts by weight) is dispersed in 100 parts by volume of corn oil and encapsulated in standard soft gelatin capsules.

EXAMPLE 4 The active ingredients of Example 2 (20 parts by weight) is dispersed in 100 parts by volume of corn oil and encapsulated in standard soft gelatin capsules.

EXAMPLE 5 Tablets for oral administration are prepared by mixing 50 milligrams of the active ingredients of Example 1, 2.5 milligrams of gelatin, 2.5 milligrams of magnesium stearate and 100 milligrams of starch, and forming the mixture into tablets by a conventional tableting machine. Slow release pills and tablets can also be used.

EXAMPLE 6 Tablets for oral administration are prepared by mixing 50 milligrams of the active ingredients of Example 2, 2.5 milligrams of gelatin, 2.5 milligrams of magnesium stearate and 100 milligrams of starch, and forming the mixture into tablets by a conventional tableting machine. Slow release pills and tablets can also be used.

EXAMPLE 7 A parenteral composition suitable for administration by injection is prepared by dissolving 5% 'by weight of the active ingredients of Example 1 in by volume of physiological saline and sterilizing the resultant solution by filtration. A buffer can be used if desired.

EXAMPLE 8 A parenteral composition suitable for administration by injection is prepared by dissolving 5% by weight of the active ingredients of Example 2 in 95% by volume of physiological saline and sterilizing the resultant solution by filtration. A buffer can be used if desired.

EXAMPLE 9 2-(5,6,7,8-tetrahydro-l-naphthylamino) 2 thiazoline (0.2 part by weight) is dissolved at a concentration of 2 milligrams per milliliter in a mixture of 25 parts by weight of polyethylene glycol (Carbowax 400) and 75 parts by weight of physiological saline. The resulting solution is then combined with an equal volume of a solution of 4 milligrams of atropine sulfate dissolved in 1 milliliter of physiological saline. The combined solution is injected into the cephalic vein of a 2 year old beagle dog so that a total of 0.1 milligram of the thiazoline and 0.2 milligram of the atropine sulfate, per kilogram of body weight of the dog, is administered. In about 15 minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-efiects.

EXAMPLE 1 O 2 (5,6,7,8 tetrahydro-l-naphthylarnino)-2-imidazoline (0.2 part by weight) is dissolved at a concentration of 2 milligrams per milliliter in a mixture of 25 parts by weight of polyethylene glycol (Carbowax 400) and 75 parts by Weight of physiological saline. The resulting solution is then combined with an equal volume of a solution of 4 milligrams of atropine sulfate dissolved in 1 milliliter of physiological saline. The combined solution is injected into the cephalic vein of a 2 year old beagle dog so that a total of 0.1 milligram of the imidazo line and 0.2 milligram of the atropine sulfate, per kilogram of body weight of the dog, is administered. In about 15 minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-effects.

EXAMPLE 1 l A 1 year old female dog is given an intravenous injection of atropine sulfate dissolved in 0.4% by weight concentration in physiological saline. The injection is sufficient to introduce 0.2 milligram of the atropine sulfate per kilogram of body weight of the dog. The injection of atropine sulfate is followed minutes later by intravenous injection of 2 (5,6,7,8 tetrahydro-l-naphthylamino)-2-thiazoline, dissolved in 0.2% by weight concentration in polyethylene glycol (25 parts) and physiological saline (75 parts), in amount sufiicient to introduce 0.1 milligram of the thiazoline per kilogram of body weight. In about minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-eifects.

EXAMPLE 12 A 1 year old female dog is given an intravenous injection of atropine sulfate dissolved in 0.4% by weight concentration in physiological saline. The injection is sufficient to introduce 0.2 milligram of the atropine sulfate per kilogram of body Weight of the dog. The injection of atropine sulfate is followed 10 minutes later by intravenous injection of 2 (5,6,7,8 tetrahydro-l-naphthylamino) 2- imidazoline, dissolved in 0.2% by weight concentration in polyethylene glycol parts) and physiological saline (75 parts), in amount sufficient to introduce 0.1 milligram of the imidazoline per kilogram of body weight. In about 15 minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-effects.

EXAMPLE l3 2-(2,3-dimethylanilino)-2-thiazoline (3 parts by weight) is dissolved in 1000 parts by Weight of a mixture of 25 parts by weight of polyethylene glycol (Carbowax 400) and 75 parts by weight of physiological saline. The resulting solution is injected intravenously into a two year-old male dog in an amount to introduce 0.132 miiigram of thiazoline per kilogram of body weight of the dog. This injection is followed in 10 minutes by intravenous administration of a normal saline solution of atropine sulfate, sufiicient to introduce 0.5 milligram of atropine sulfate per kilogram of body weight of the dog. In about 15 minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state 6 lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-effects.

EXAMPLE 14 2 (2,3 dimethylanilino) 2 imidazoline (3 parts by weight) is dissolved in 1000 parts by weight of a mixture of 25 parts by weight of polyethylene glycol (Carbowax 400) and parts by Weight of physiological saline. The resulting solution is injected intravenously into a 2 yearold male dog in an amount to introduce 0.132 milligram of imidazoline per kilogram of body weight of the dog. This injection is followed in 10 minutes by intravenous administration of a normal saline solution of atropine sulfate, sufiicient to introduce 0.5 milligram of atropine sulfate per kilogram of body Weight of the dog. In about 15 minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-efiects.

EXAMPLE 15 Example 13 is repeated, except that scopolamine hydrobromide is used in place of the atropine sulfate, with similar results.

EXAMPLE 16 Example 14 is repeated, except that scopolamine hydrobromide is used in place of the atropine sulfate, with similar results.

EXAMPLE 17 Example 11 is repeated, except that in place of the atropine sulfate there is used an amount of phenyl cyclopentylglycolic acid, N-ethylpiperidinol ester, suflicient to introduce 0.2 milligram of the ester per kilogram of body weight of the dog, with similar results.

EXAMPLE 18 Example 12 is repeated, except that in place of the atropine sulfate there is used an amount of phenyl cyclopentylglycolic acid, N-ethylpiperidinol ester, sufficient to introduce 0.2 milligram of the ester per kilogram of body weight of the dog, with similar results.

EXAMPLE 19 Example 9 is repeated, except that in place of the atropine there is used an amount of benzilic acid, betadiethylaminoethyl ester, sufficient to introduce 0.1 milligram of the ester per kilogram of body weight of the dog, with similar results.

EXAMPLE 20 Example 10 is repeated, except that in place of the atropine there is used an amount of benzilic acid, betadiethylaminoethyl ester, sufiicient to introduce 0.1 milligram of the ester per kilogram of body weight of the dog, with similar results.

EXAMPLE 21 Rhesus monkeys are exposed for 5 minutes in a dynamic chamber to an atmosphere containing 400 micrograms per liter of 2-(5,6,7,8tetrahydro-l-naphthylamino)-2- thiazoline and 800 micrograms per liter of scopolarnine aspirated into the chamber in the form of an aerosol. Within 3 to 5 minutes the animals become prostrate, severely depressed and apparently unconscious for a period of about 1 hour.

EXAMPLE 22 Rhesus monkeys are exposed for 5 minutes in a dynamic chamber to an atmosphere containing 400 micrograms per liter of 2-(5,6,7,8-tetrahydro-1-naphthylamino)-2-imidazoline and 800 micrograms per liter of scopolamine aspirated into the chamber in the form of an aerosol. Within 3 to 5 minutes the animals become prostrate, severely depressed and apparently unconscious for a period of about 1 hour.

EXAMPLES 2352 The procedures of Examples 9, 10, 11 and 12 are repeated except that the following listed anticholinergic agents and thiazollnes or irnidazolines are substituted in like amounts by Weight for those of Examples 9, 10, ll and 12 respectively. They are administered in like manner and provide like results.

Amount Amount Example (mg/kg.) (mg/kg.) Antlchollnergic 0.25 2-(1-naphty1amino)-2 thiazo1ine 0. 500 Atropine sulfate. 0. 25 Z-(I-naphthylamlno)-2-imidazoll 0.500 Do.

0.2 2-(4-methoxy-l-naphthylamino)-2-thlazoline. 0. 400 Scopolamine hydrobromlde. 0. 2 2-(4-methoxy-l-naphthylamlno)-2-lmldazoline 0. 400 Do. 0.2 2-(4-methoxy-1-naphthylamlno)-2-thlaz0llne 5. Benzotyzine. 0. 2 2-(i-mathoxy-l-naphthylamino)-2-lmldazollne.. 5.00 Do. 0. 2 2-(2-methyl-l-naphthylamlno)-2-thlazoline 0. 400 Scopolarnlne hydrobromlde. 0. 2 2-(2-methyl-l-naphthylamlno)-2-imldazollne 0. 400 Do. 1.0 2-(4-methyl-1-naphthylamino)-2-thlazollne 1.00 Atropine sulfate. 1. 0 2-(4-methyl-l-naphthylamlno)-2imldazollne 1.00 D 0. 0.1 2-(5,6,7,B-tetrahydro-l-naphthylamino) -2-thlazollne 10.00 Trasentino. 0. 1 2-(5,6,7,S-tetrahydro-l-naphthylarnino)-2-lmldaz0llne 10. 00 Do. 0. 1 2-(4-metliyl-5,6,7,s-tetrahydro-l-naphthylamlno)-2-tl11azoline 0. 50 Benztropine. 0.1 2-(4-methyl-5,6,7,8-tetrahydro-1naphthylamlno)-2-lmidazollne 0.50 Do. 0.5 2-(4-methoxy-5,6,7,8-tetrahydro-l-naphthylamlno)-2-thlazollne 1. 00 Dltran 0. 5 2-(4-methoxy-5,6,7,8-tetrahydro-1-naphthylamluo)-2-imldazollne 1. 00 D0. 0. 1 2-(1,2,3,4-tetrahydro-l-naphthylamlno)-2-thlaz0llne. 25. 00 Caramiphen. 0. 1 2-(1,2,3,4-tetrahydro-l-naphthylamino)-2-imldazollne 25.00 0. 0.25 2-(2-methylanilino)-2-thiazoline 0.50 Oyclopentolate. 0.25 2-(2-methylanilino) -2-imldazoline 0.50 o.

0. 5 2-(2-ethylanlliuo)-2-thlazoline 5.00 Cycrimine hydrochloride. 0.5 2-(2-ethylanilion)-2-i.midazollne 5. 00 Do. 0. 1 2(2,3-dimethylanilino)-2-thlazoline. 50. 00 Ethopropazine. 0. 1 2-(2,3-dimethylanillno)2-lm1dazollno 50.00 Do. 0. 2-(2-chloro-2-methylanillno) -2-thlaz0line 50. 00 Plparldolate. 0.25 2-(2-chloro-2-methylanillno)-2-imidazoline 50. 00 Do.

0. 1 2-(2,6-dlmethylanlliuo)-2-thiazoline 20.00 Oxyphencyclimine. 0. 1 2-(2,6-dlmethylanilino)2lrnidazoline 20. 00 Do. 0. 75 244-111ethoxy-Zqnethylanillno) -2-thiazoline 5.00 Trlcyclamol. 0.75 2-(4 methoxy-2-methylan1lino) -2-lmidazoline 5. 00 Do.

where in each of Formulas 1 through 6 X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each separately selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in these four substituents being a maximum of 8; where in each of Formulas 1 through 5, 1 through 3 hydrogen atoms of the moiety selected from the group consisting of naphthyl, partially reduced naphthyl and indanyl can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethly and trifluoromethoxy; and wherein Formula 6 A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; B is selected from the group consisting of alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; and C is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, halogen, alkylthio of 1 through 4 carbons, alkoxyalkyl wherein the alkoxy portion has 1 through 2 carbons and the alkyl portion has 1 through 2 carbons, alkylamino of 1 through 2 carbons, dialkylamino where each alkyl group has 1 through 2 carbons, trifiuoromethyl and tritluoromethoxy.

2. The method according to claim 1 wherein said centrally acting anticholinergic is N-ethyl-3-piperidylphenylcyclopentyl glycolate.

3. The method comprising administering to a Warmblooded animal Within an hour of each other from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifluoromethoxy.

4. The method comprising administering to a warmblooded animal Within an hour of each other from 0.5

to parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and Where 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy.

5. The method comprising administering to a warmblooded animal within an hour of each other, from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromcthoxy.

6. The method comprising administering to a Warmblooded animal within an hour of each other, 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by Weight of a compound of the formula R X*G R 1 NCR L a where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy.

7. Method comprising administering to a warm-blooded animal within an hour of each other, 0.5 to 30 parts by Weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in eachof these 4 substituents being a maximum 'of 8;.and where 1 through 3 of the hydrogen atoms in the-indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 'mrbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluorornethyl and trifluoromethoxy. I 7' 8. The method comprising administering to a warmblooded animal within an hour of each other 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; B is selected from the group consisting of alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; and C is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, halogen, alkylthio of 1 through 4 carbons, alkoxyalkyl wherein the alkoxy portion has 1 through 2 carbons and the alkyl portion has 1 through 2 carbons, alkylamino of 1 through 2 carbons, dialkylamino where each alkyl group has 1 through 2 carbons, trifluoromethyl and trifluoromethoxy.

9. The method according to claim 1 where said anticholinergic agent is atropine sulfate and the second ingredient is 2-(5,6,7,8-tetrahydro-l-naphthylamino)-2-thiazoline.

10. The method according to claim 1 where said anticholinergic agent is atropine sulfate and the second ingredient is 2-(5,6,7,S-tctrahydro-l-naphthylamino)-2irnidazoline.

11. The method according to claim 1 where said anticholinergic agent is atropine sulfate and the second ingredient is 2-( 2,3-dimethylanilino -2-thiazoline.

12. The method according to claim 1 where said anticholinergic agent is atropine sulfate and the second ingredient is 2-(2,3-dimethylanilino) -Z-imidazoline.

'13. The method according to claim 1 where said anticholinergic agent is scopolamine hydrobromide and the second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino)-2-thiazoline.

14. The method according to claim lwhere said anticholinergic agent is scopolamine hydrobromide and the second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino)-2-imidazo1ine.

15. The method according to claim 1 where said anticholinergic agent is scopolamine hydrobromide and the second ingredient is 2-(2,3-dimethylanilino)-2-thiazoline.

16. The method according to claim 1 where said anticholinergic agent is scopolamine hydrobromide and the second ingredient is 2-(2,3-dimetliylanilino)2-imidazoline.

17. The method according to claim 1 where said anticholinergic agent is selected from the, group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino)-2-thiazoline.

18. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the 17 second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino) -2-imidazoline.

19. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino) 2 thiazoline.

20. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino) 2 irnidazoline.

21. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(5,6,7,8-tetrahydro l naphthylamino)-2-thiazoline.

22. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino)-2-imidazoline.

23. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino)-2-thiazoline.

24. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino) 2 irnidazoline.

25. A composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula Where in each of the Formulas 1 through 6 X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each separately selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in these four substituents being a maximum of 8; where in each of Formulas 1 through 5, 1 through 3 hydrogen atoms in the moiety selected from the group consisting of naphthyl, partially reduced naphthyl and indanyl can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy; and Where in Formula (6) A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; B is selected from the group consisting of alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; and C is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoXy of 1 through 4 carbons, halogen, alkylthio of 1 through 4 carbons, al-

koxyalkyl wherein the alkoxy portion has 1 through 2 carbons and the alkyl portion has 1 through 2 carbons, alkylamino of 1 through 2 carbons, dialkylamino where each alkyl group has 1 through 2 carbons, trifluoromethyl and trifluoromethoxy.

26. A composition according to claim 25 Where said centrally acting anticholinergic agent is N-ethyl-3-piperidylphenylcyclopentylglycolate.

27. A composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifluoromethoxy.

28. A composition comprising from 0.5 to 30 parts by Weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy.

29. A composition comprising from .5 to 30 parts by Weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula Where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and Where 1 through 3 of the hydrogen atoms in the indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethyl and trifiuoromethoxy.

30. A composition comprising from 0.5 to 30 parts by Weight of a centrally acting anticholiner gic agent and l part by Weight of a compound of the formula Where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced consisting of halogen, alkyl f 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifluoromcthoxy.

31. A composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by Weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethyl and trifluoromethoxy.

32. A composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; B is selected from the group consisting of alkyl of I through 4 carbons, alkoxy of 1 through 4 carbons and halogen; and C is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, halogen, alkylthio of 1 through 4 carbons, alkoxyalkyl wherein the alkoxy portion has 1 through 2 carbons and the alkyl portion has 1 through 2 carbons, alkylamino of 1 through 2 carbons, dialkylamino Where each alkyl group has 1 through 2 carbons, trifiuoromethyl and trifi uoromethoxy.

33. A composition comprising 1 part by weight of 2- 5,6,7 ,8 tetrahydro l-naphthylamino)-2-thiazoline and 0.5-30 parts by Weight of atropine sulfate.

34. A composition comprising 1 part by weight of 2- 5 ,6,7,8-tetrahydrol-naphthylamino -2-imidazoline and 0.530 parts by weight of atropine sulfate.

35. A composition comprising 1 part by Weight of 2- (2,3-dimethylanilino)-2-thiazoline and 0.5-3O parts by weight of atropine sulfate.

36. A composition comprising 1 part by weight of 2- (2,3-dimethylanilino)-2-imidazoline and 0.5-30 parts by weight of atropine sulfate.

37. A composition comprising 1 part by weight of 2- (5,6,7,8 tetrahydro l-naphthylamino)-2-thiazoline and O.53O parts by weight of scopolamine hydrobromide.

38. A composition comprising 1 part by weight of 2- (5,6,7,8-tetrahydro-1-naphthylamino)-2-imidazoline and 0.5-3O parts by weight of scopolamine hydrobromide.

39. A composition comprising 1 part by weight of 2- (2,3-dimethylanilino)-2-thiazoline and 0.5 to 30 parts by weight of scopolamine hydrobromide.

40. A composition comprising 1 part by weight of 2- (2,3-dimethylanilino)-2-imidazoline and 0.5 to 30 parts by Weight of scopolamine hydrobromide.

41. A composition comprising 1 part by Weight of 2- (5,6,7,8-tetrahydro-l-naphthylamino) 2 thiazoline and 0.530 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N- ethylpiperidinol ester and benzilic acid, beta diethyl aminoethyl ester.

42. A composition comprising 1 part by Weight of 2- (5,6,7,8-tetrahydro-l-naphthylamino) Z-imidazoline and 0.5-30 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N- ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester.

43. A composition comprising 1 part by weight of 2- (2,3-dirnethylanilino)-2-thiazoline and 0.5-30 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester.

44. A composition comprising 1 part by weight of 2-(2,3-dirnethylanilino)-2-imidazoline and 0.530 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester.

45. A composition comprising 1 part by weight of 2-(5,6,7,8,-tetrahydro-l-naphthylamino) 2-thiazoline and 0.5-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.

46. A composition comprising 1 part by weight of 2-(5,6,7,8-tetrahydro-l-naphthylamino)-2-imidazo1ine and 05-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.

47. A composition comprising 1 part by weight of 2-(2,3-dimethy1anilino)-2-thiazo1ine and 05-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.

48. A composition comprising 1 part by weight of 2-(2,3-dimethylani1ino)-2-imidaz01ine and 0.5-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.

22 References Cited UNITED STATES PATENTS 3,287,469 11/1966 Harvey 2603 09.6 2,027,031 1/ 193 6 Engelmann 26044 2,870,160 1/1959 Bloom 260307 3,287,469 11/1966 Harvy 260309.6

LELAND A. SEBASTIAN, Primary Examiner US. Cl. X.R

260306.8 R, 309.6; 424247, 251, 267, 268, 269, 270, 273 and 274

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3882229 *Nov 8, 1973May 6, 1975Nordmark Werke GmbhComposition and method for shrinking mucous membranes
US3978221 *Mar 4, 1975Aug 31, 1976Smithkline CorporationMethods for improving the feed intake of meat producing animals
US4269990 *Dec 5, 1979May 26, 1981Basf Aktiengesellschaft1-Acyl-2-imidazolines and their manufacture
US4287201 *Mar 3, 1980Sep 1, 1981Merck & Co., Inc.Anovulatory method and chicken feed compositions
US4363751 *May 20, 1981Dec 14, 1982Merck & Co., Inc.Mixed oxide of manganese, chromium and molybdenum for ammoxidation
US4461904 *Nov 20, 1981Jul 24, 1984Alcon Laboratories, Inc.Lowering intraocular pressure, glaucoma
US4476135 *Feb 16, 1982Oct 9, 1984Sandoz Ltd.Amino-2,1,3-benzothiadiazole and -benzoxadiazole derivatives, their preparation and pharmaceutical compositions containing them
US4515800 *Aug 3, 1983May 7, 1985Icilio CaveroMethod of lowering intraocular pressure using phenylimino-imidazoles
US4517199 *Aug 3, 1983May 14, 1985Alcon Laboratories, Inc.Treatment of glaucoma
US4644007 *Jul 15, 1985Feb 17, 1987Alcon Laboratories, Inc.3-chloro-4-(4,5-dihydro-1H-imidazo-2-yl)-amino-5-alkylbenzoic acids, esters, salts, compositions and methods
US4788209 *Feb 17, 1987Nov 29, 1988Merrell Dow Pharmaceuticals Inc.Infections of skin and mucous membranes
US5066664 *Feb 28, 1990Nov 19, 1991Allergan, Inc.2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents
US5091528 *Sep 12, 1990Feb 25, 1992Allergan, Inc.6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5151440 *Feb 28, 1990Sep 29, 1992Allergan, Inc.Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5180721 *May 30, 1991Jan 19, 1993Allergan, Inc.Imidazoline substituted naphthalene compounds for treatment of glaucoma
US5223498 *Dec 28, 1989Jun 29, 1993The Boots Company PlcPhenylamidine and phenylguanidine derivatives and their use as antidiabetic agents
US5252595 *Aug 5, 1992Oct 12, 1993Allergan, Inc.Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5281591 *Oct 28, 1992Jan 25, 1994Allergan, Inc.Administering amidoimido ester or thioamidoimido ester derivative
US5580892 *Oct 22, 1993Dec 3, 1996AllerganAntidiarrhetic, antispastic, antiepileptic agents; diuretics
US5708015 *Oct 29, 1996Jan 13, 1998AllerganMethod for using pharmaceutical compositions containing 2-(2-alkyphenyl-amino)-thiazolines as adrenergic agents
US5731337 *Oct 3, 1995Mar 24, 1998AllerganConformationally rigid bicycle and adamantane derivatives useful as α2
US6093727 *Oct 20, 1998Jul 25, 2000Synaptic Pharmaceutical CorporationA selective agonists for human alpha 2 receptors for treating disorders as hypertension, pain, glaucoma, alcohol and drug withdrawal, ischemia, rheumatoid arthritis, migraine, cognitive deficiency, spasticity, diarrhea, nasal congestion
US6150389 *Jan 7, 1998Nov 21, 2000Allergan Sales, Inc.Antidepressants; treating elevated intraocular pressure, e.g., glaucoma; antidiabetic agents for non-insulin dependent diabetes, sexual disorders, e.g., male impotence and obesity; e.g. trans-2-(3-phenyl-bicyclo(2.2.1)heptyl)-2-aminooxazoline
US6294566Sep 20, 1999Sep 25, 2001Synaptic Pharmaceutical CorporationImidazoline derivatives and uses thereof
US6319935Apr 4, 2000Nov 20, 2001Allergan Sales, Inc.Used in treatment of elevated intraocular pressure, non insulin-dependent diabetes, male impotence and obesity
US6353006Dec 3, 1999Mar 5, 2002Bayer CorporationSubstituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
US6569884May 1, 2001May 27, 2003AllerganConformationally rigid bicyclic and adamantane derivatives useful as α2-adrenergic blocking agents
US6706747Mar 19, 2003Mar 16, 2004Allergan, Inc.Treating elevated intraocular pressure, depression, non insulin-dependent diabetes, male impotence and obesity which is alleviated by treatment with an alpha 2 blocking agent
US6777426Aug 20, 2001Aug 17, 2004Synaptic Pharmaceutical CorporationImidazole and imidazoline derivatives and uses thereof
US7179829 *Jul 16, 2004Feb 20, 2007Sanofi-Aventis Deutschland GmbhSuch as trans-(2-chloro-6-trifluoromethylphenyl)-(octahydrobenzimidazol-2-ylidene)amine hydrochloride; for treatment/prophylaxis of central nervous system disorders, lipid metabolism, infection by ectoparasites, disorders of gall function, improving respiratory drive/snoring
US7960310Aug 2, 2006Jun 14, 2011Syngenta Participations AgMethod of combating and controlling insects
US7981437 *Nov 15, 2006Jul 19, 2011Basf SeIndanyl- and tetrahydronaphthyl-amino-azoline compounds for combating animal pests
US8178567Feb 2, 2007May 15, 2012Fmc CorporationInsecticidal substituted amino heterocyclic and heteroaryl derivatives
US8309739May 11, 2011Nov 13, 2012Syngenta LimitedChemical compounds
US8815923Mar 29, 2013Aug 26, 2014Allergan, Inc.Therapeutic compounds
EP0081924A1 *Nov 19, 1982Jun 22, 1983Alcon Laboratories, Inc.Topical compostions for lowering intraocular pressure
WO1995011021A1 *Oct 20, 1994Apr 27, 1995Allergan IncUse of 2-(2-alkylphenylamino)-oxazolines, -thiazolines and -imidazolines as alpha 2 adrenergic agents
WO1998046572A1 *Apr 10, 1998Oct 22, 1998Synaptic Pharma CorpImidazole and imidazoline derivatives and uses thereof
WO2009023757A1 *Aug 14, 2008Feb 19, 2009Allergan IncTherapeutic compounds
WO2009023758A1 *Aug 14, 2008Feb 19, 2009Allergan IncHeterocyclyl substituted fused carbocyles useful in the treatment of conditions such as glaucoma and pain
WO2011044229A1Oct 6, 2010Apr 14, 2011Allergan, Inc.2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators
Classifications
U.S. Classification514/291, 548/198, 514/304, 548/193, 548/331.5, 548/333.1, 514/370, 548/190, 514/398, 514/327
International ClassificationC07D277/18, C07D233/50
Cooperative ClassificationC07D233/50, C07D277/18
European ClassificationC07D277/18, C07D233/50